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eliminated with the bile. Thus, risk for gallstones 
is greatly increased.5 Moreover, insulin resistance 
and type 2 diabetes mellitus act as independent 
factors associated with gallstone disease.6,7 Hy­
perinsulinemia is related to increased hepatic cho­
lesterol uptake, biliary secretion, and hyposecre­
tion of biliary bile acids.3 In contrast, gallstone 
disease is associated with increased risk of inci­
dent ischemic heart disease, independent of tra­
ditional risk factors.8 In the German population, 
people with gallstones were at increased risk of 
myocardial infarction and stroke; however, they 
INTRODUCTION Gallstone disease is a significant 
health problem in developed societies, affecting 
5% to 25% of the adult population.1,2 Epidemio­
logical studies have indicated a large number of 
risk factors for cholesterol stones. Physical inac­
tivity and overnutrition are known risk factors 
for obesity and metabolic syndrome.3 Increas­
ing prevalence of obesity, diabetes mellitus, and 
related adipose tissue dysfunction will be a rele­
vant trigger for cardiovascular diseases.4 During 
excessive intake of food, the synthesis of whole­
­body cholesterol is promoted , and its excess is 
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ABSTRACT
INTRODUCTION Gallstone disease is associated with insulin resistance, type 2 diabetes mellitus, and 
increased risk of incident ischemic heart disease. It is known that the profile of branched ‑chain amino 
acids (BCAAs) is altered in cardiac diseases as well as metabolic diseases, such as diabetes and obesity. 
The role of BCAAs in gallstone disease is still not known.
OBJECTIVES The aim of this study was to evaluate the concentration of essential amino acids and 
incretin hormones in patients with cholecystolithiasis.
PATIENTS AND METHODS The study included 31 patients with cholecystolithiasis and 25 gallstone ‑free 
controls. The levels of free exogenous and endogenous amino acids, bile acids, glucagon ‑like peptide 1, 
glucose ‑dependent insulinotropic polypeptide, ghrelin, C‑peptide, and insulin were measured in the fast‑
ing state and 1 hour after consumption of a 300 ‑kcal mixed meal.
RESULTS The mean fasting and postprandial levels of valine, isoleucine, leucine, and lysine were higher 
in the study group than in controls (all P <0.01). The percentage increase in concentrations of amino 
acids after a meal were similar in both groups of patients. The mean fasting concentrations of C ‑peptide 
and glucagon ‑like peptide 1 were higher in the study group than in the control group (P = 0.004 and 
P = 0.03, respectively), and the median postprandial concentration of C ‑peptide was higher in the study 
group as compared with the control group (P = 0.03).
CONCLUSIONS Diabetes mellitus, coronary heart disease, and gallstone disease might have common 
genetic and environmental antecedents. However, higher plasma levels of BCAAs observed in patients 
with gallstone disease may be partly responsible for metabolic complications observed in these patients.
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mellitus.16,17 GLP ­1 analogues induce activation 
of the GLP ­1 receptor, which stimulates insulin 
secretion in a glucose ­dependent fashion while 
also inhibiting secretion of glucagon. The use of 
GLP ­1 analogs was associated with an increased 
risk of bile duct and gallbladder disease.16
The aim of this study was to evaluate the con­
centration of essential amino acids and incretin 
hormones in patients with cholecystolithiasis.
PATIENTS AND METHODS Thirty ­one consecu­
tive patients with symptomatic gallstone disease 
scheduled for elective surgery (laparoscopic cho­
lecystectomy) were selected for the study group 
(21 women, mean age [SD], 56.2 [12.9] years; 10 
men, mean age (SD), 51.5 [12.7] years). Gallstones 
were visualized in the gallbladder on ultrasound 
examination before the operation. Patients pre­
sented with mild, recurrent episodes of biliary 
colic. None of these patients had associated cho­
ledocholithiasis or acute cholecystitis. The con­
trol group consisted of 25 consecutive patients 
(18 women, mean age [SD], 47.0 [15.7] years; 7 
men, mean age [SD], 67.1 [7.5] years) who were 
treated for hernias or had colonoscopy examina­
tion and had no pre­ or intraoperative signs of 
cholelithiasis or jaundice. All patients were sur­
gically treated at the Department of General and 
Oncological Surgery (St. John Grande Hospital in 
Kraków) from 2017 to 2018. The characteristics 
of the study population are presented in TABLE 1. 
White blood cell count, concentrations of glucose, 
thyroid stimulating hormone, and free thyroxine 
were comparable between the study and control 
groups, while body mass index (BMI) was higher 
in the study group.
Fasting venous blood samples and venous 
blood samples 1 hour after the consumption of 
a 300 ­kcal mixed meal that was comprised of 24% 
protein, 41% carbohydrates, and 35% fat (Nutrid­
rink protein, 125 ml, Nutricia, Zoetermeer, the 
Netherlands), were collected from all patients 
separately on lithium heparin and on EDTA with 
aprotinin. Blood was additionally collected to 
tubes containing a clot activator in order to ob­
tain the serum for further analyses. The blood 
was centrifuged for 10 minutes at 1200 × g, and 
the plasma and serum were collected and kept 
at –70°C until analysis. Quantitative determina­
tion of plasma free amino acids was performed 
by the Pico ­Tag method (Waters, Milford, Mas­
sachusetts, United States). Samples were ana­
lyzed by a high ­performance liquid chromatog­
raphy with UV –VIS detection (Waters) as previ­
ously described by Bugajska et al.18 The essential 
amino acids: Val, Ile, Leu, threonine, methionine, 
Phe, Lys, tryptophan, histidine and nonessential 
amino acids: arginine (Arg), tyrosine (Tyr), aspar­
tic acid, glutamic acid, hydroxyproline, serine, as­
paragine, glycine, glutamine, taurine, citrulline, 
alanine, proline, α ­aminobutyric acid, ornithine 
were determined.
The total bile acid content was measured us­
ing an enzymatic colorimetric method (bile acid, 
did not experience a lowered cardiovascular risk 
after gallbladder removal.9 It has also been re­
ported that alterations in the profiles of essen­
tial amino acids in the blood are associated with 
cardiovascular disease (CVD).10
Essential amino acids necessary for proper hu­
man development are not synthesized in the body 
and must be ingested with food (exogenous essen­
tial amino acids such as isoleucine [Ileu], leucine 
[Leu], lysine [Lys], methionine, phenylalanine 
[Phe], threonine, tryptophan, valine [Val], and 
histidine). Among these essential amino acids, 
branched ­chain amino acids (BCAAs) (Val, Leu, 
and Ileu) are abundant in food, accounting for ap­
proximately 20% of total protein intake.11 Despite 
clinical evidence suggesting that the supplemen­
tation of essential amino acids or BCAAs has ben­
eficial effects on body weight, body fat, lean body 
mass, and insulin sensitivity, the increased levels 
of BCAAs may cause insulin resistance and type 
2 diabetes mellitus.11,12 Higher concentrations of 
BCAAs in plasma are associated with increased 
risk of CVD, especially stroke.13 In patients after 
myocardial infarction, cardiac BCAAs catabolism 
is impaired, resulting in myocardial BCAAs accu­
mulation. Subsequently, BCAAs activate myocar­
dial mammalian target of rapamycin signaling and 
contribute to cardiac dysfunction and remodel­
ing following myocardial infarction.14 The role of 
BCAAs in gallstone disease is not known, and to 
our knowledge there are no data linking BCAAs 
with the risk of this disease.
Gastrointestinal hormones (glucagon ­like 
peptide ­1 [GLP ­1], glucose ­dependent insulinotro­
pic polypeptide [GIP]), known as incretins, stim­
ulate insulin secretion at physiological concentra­
tions. The incretin activity is linked to the gastro­
intestinal processing of ordinary meals.15 New 
drugs have been developed for diabetes ther­
apy. Incretin ­based drugs, such as GLP ­1 ana­
logues, are relatively new antidiabetic therapies 
recommended for patients with type 2 diabetes 
WHAT’S NEW?
Branched ‑chain amino acids (valine, isoleucine, leucine), the profile of which is 
altered in gallstone disease, may link gallstone disease with insulin resistance, 
type 2 diabetes mellitus, and cardiometabolic syndrome.
TABLE 1 Characteristics of the study populations
Variable Study group 
(n = 31)
Control group 
(n = 25)
P value
Body mass index, kg/m2 29.7 (3.39) 26.3 (3.28) <0.001
White blood cell count, ×109/l 6.57 (1.55) 6.57 (1.53) 0.99
Fasting blood glucose, mmol/l 5.56 (0.56) 5.52 (0.66) 0.84
TSH, mIU/l 1.51 (0.81–4.18) 1.52 (1.03–1.88) 0.63
FT4, pmol/l 16.9 (1.9) 17.2 (2.2) 0.55
Data are presented as mean (SD) or median (interquartile range).
Abbreviations: FT4, free thyroxine; TSH, thyroid stimulating hormone
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of nonnormal distribution, the Mann–Whitney 
test was used. The level of significance was set at 
a P value of less than 0.05.
RESULTS The concentrations of plasma essen­
tial amino acids of patients with cholelithiasis 
and controls are presented in FIGURE 1. The fasting 
and postprandial values of Val, Ile, Leu (BCAAs), 
and Lys were higher in the study group than in 
the control group (all P <0.01).
The fasting and postprandial values of total bile 
acids, hormones and nonessential amino ac­
ids concentrations obtained in the study group 
and in the control group are presented in TABLE 2. 
The fasting concentrations of Tyr, glutamic acid, 
alanine, proline, and ornithine were higher in 
the study group than in controls (P = 0.009, 
P = 0.02, P = 0.03, P = 0.02, and P = 0.03, re­
spectively). The postprandial concentrations of 
Arg, Tyr, proline, α ­aminobutyric acid, and orni­
thine were higher in the study group than in con­
trols (P = 0.01, P = 0.006, P = 0.02, P = 0.04, and 
P = 0.02, respectively). The values of other amino 
acids were similar in both study groups. The per­
centage increases in concentrations of amino acids 
after a meal were the same in both study groups.
The fasting concentrations of C ­peptide and 
GLP ­1 were higher in the study group than in 
the control group (P = 0.004 and P = 0.03, respec­
tively). The postprandial concentration of C ­pep­
tide was higher in the study group than in the con­
trol group (P = 0.03). There were no differences 
Randox Laboratories Ltd., Crumlin, United King­
dom). Enzyme ­linked immunosorbent assay kits 
were used to assay plasma GLP­1 (Millipore, Bill­
erica, Massachusetts, United States), plasma ghre­
lin (Millipore), and GIP (Immuno ­Biological Lab­
oratories Co. Ltd., Fujioka, Japan). Serum C­pep­
tide concentrations were measured with radioim­
munoassay method (DIAsource C ­PEP II­ RIA ­CT 
Kit, Louvain­la­Neuve, Belgium).
Insulin, thyroid stimulating hormone, and free 
thyroxine concentrations were determined using 
the immunochemiluminescence method, with 
the ADVIA Centaur XP equipment (Tarrytown, 
New York, United States).
The study was approved by the Jagiellonian 
University Bioethics Committee (protocol no. 
1072.6120.44.2017). All patients who participat­
ed in the study signed a free and informed con­
sent form and were fully informed on all aspects 
related to the study. The study was conducted fol­
lowing all ethical and legal regulations.
Statistical analysis Descriptive statistics (mean 
[SD], medians [interquartile ranges]) were used 
in the statistical assessment of the obtained re­
sults. Calculations were performed using the Sta­
tistica software version 10 (StatSoft, Kraków, Po­
land) and Microsoft Office Excel 2003 (Redmond, 
Washington, United States). The Shapiro–Wilk 
test was used to test the normality of variables. 
To compare parameters between the study group 
and the control group for normally distributed 
continuous variables, the t test was used, in case 
FIGURE 1 Concentrations of essential amino acids (mean [SD]) in plasma of patients with cholelithiasis and controls 
a    P <0.001 compared with the control group;   b     P = 0.005 compared with the control group 
Abbreviations: His, histidine; Ileu, isoleucine; Leu, leucine; Lys, lysine; Met, methionine; Phe, phenylalanine; Thr, threonine; Trp, tryptophan;  Val, valine
100
0
Val Ileu Leu Thr
Branched-chain
amino acids
Met Phe Lys Trp
a
a
a
a
a
a
a
b
His
200
μm
ol
/l
300
400
500
Fasting
Postprandial
Postprandial
Fasting
Control group
Study group
POLISH ARCHIVES OF INTERNAL MEDICINE 2019; 129 (12)886
In the present study, the mean or median val­
ues of BCAAs, Tyr, C ­peptide, and insulin concen­
trations were higher in patients with cholelithia­
sis than in controls; however, for insulin, the dif­
ference was not significant. This is in agreement 
with the results obtained by Mendez ­Sanchez et 
al,25 who analyzed the serum concentrations of 
insulin in patients with cholecystolithiasis and 
noticed a greater tendency towards insulin resis­
tance in that group than in controls.
Altered metabolism of BCAAs and their sub­
sequent accumulation in the blood may precede 
the development of insulin resistance and clini­
cal manifestation of cardiometabolic diseases.26 
Increased BCAAs levels are independent risk fac­
tors of metabolic syndrome and CVD in middle­
­aged and elderly Chinese populations.27 Shah 
et al28 used quantitative mass spectrometry to 
measure metabolomic profiles in 117 individu­
als within 8 multiplex families from the GEN­
ECARD (Genetics of Early Onset Cardiovascu­
lar Disease) study of premature coronary artery 
disease, and the results revealed that some ami­
no acids (Arg, ornithine, alanine, proline, Leu, 
Ile, Val, glutamine, Phe, and glycine) were high­
ly heritable and could be used to identify families 
for total bile acids, insulin, ghrelin, and GIP be­
tween the 2 groups.
DISCUSSION The prevalence of gallstone disease 
is higher in diabetic patients than in the general 
population with comparable characteristics (MI­
COL [Multicenter Italian Study on Cholelithiasis] 
study) (24.8% and 13.8%, respectively).19,20 The me­
ta­analysis by Weng et al21 supported the viewpoint 
that type 2 diabetes mellitus increases the risk of 
gallstone disease. Association between gallstone 
disease and type 2 diabetes mellitus is frequently 
linked to obesity.21 Furthermore, the association 
between high BMI and gallstone disease might be 
explained by insulin resistance. Gallbladder dys­
motility might, thereby, be the mechanism of gall­
stone formation in insulin resistance.6 Caroli et 
al22 found a positive association between higher 
C ­peptide levels and cholelithiasis in diabetic pa­
tients. Würtz et al23 have shown that circulating 
BCAAs (Ile, Leu, Val) and aromatic amino acids 
(Phe, Tyr) from fasting serum are predictors of in­
sulin resistance, but not glycemia, in young adults 
at a 6 ­year follow ­up. BCAAs likely promote insu­
lin resistance through activation of mammalian 
target of rapamycin complex.24
TABLE 2 Fasting and postprandial plasma mean concentrations of total bile acids, hormones, and nonessential amino acids in the study group and 
the control group
Variable                                                 Fasting               Postprandial
Study group 
(n = 31)
Control group 
(n = 25)
P value Study group  
(n = 31)
Control group 
(n = 25)
P value
Total bile acids, μmol/l 1.47 (0.81–2.73) 1.46 (1.03–2.64) 0.39 2.92 (1.61–4.82) 2.5 (1.54–3.18) 0.37
Hormones
Insulin, μIU/ml 11.58 (6.22) 9.11 (3.73) 0.16 66.09 (39.35) 44.9 (21.2) 0.06
C ‑peptide, ng/ml 2.99 (1.13–6.16) 2.29 (1.49–3.92) 0.004 7.44 (5.42–8.75) 5.3 (4.87–6.7) 0.03
Ghrelin, pg/ml 643.6 (233.5) 691.1 (285.3) 0.60 598.4 (195.7) 620.2 (263.4) 0.78
GLP ‑1, pmol/l 38.7 (16.5) 27.1 (7.64) 0.03 49.7 (18.2) 39.0 (12.3) 0.07
GIP, pmol/l 30.8 (23.9–36.3) 27.8 (17.6–36.0) 0.19 205.7 (169.6–208.7) 171.9 (137–208) 0.32
Nonessential amino acids, μmol/l
Arginine 114.4 (98.6–144.2) 112.8 (91.6–120.7) 0.37 149.3 (141.2–178.9) 128.1 (109.5–147) 0.01
Tyrosine 69.5 (60–72.7) 60.8 (53.9–71.1) 0.009 100.2 (19.9) 84.4 (21.6) 0.006
Aspartic acid 6.2 (2.3–11.9) 4.3 (1.75–8.4) 0.14 5.8 (2.2–13.3) 3.2 (2–9.7) 0.2
Glutamic acid 120 (61.1–209.3) 89.4 (49.9–162.4) 0.02 141.8 (76.3–263.6) 92.2 (54.5–183.3) 0.07
Hydroxyproline 8.3 (6.6–13.3) 8.1 (6.35–11.4) 0.14 9 (7.9–14.7) 8.5 (7.2–11.9) 0.31
Serine 110.4 (27.5) 117.5 (28.0) 0.34 135.1 (33.0) 153.2 (36.5) 0.06
Asparagine 59.9 (47.7–68.9) 60.2 (48.9–68.9) 0.84 82.0 (73.2–92.0) 81.1 (74.0–90.9) 0.81
Glycine 212.6 (60.5) 213.2 (64.0) 0.97 215.6 (58.3) 224.3 (67.6) 0.61
Glutamine 701.1 (146.6) 657.0 (123.9) 0.24 772.0 (150.3) 753.7 (168.3) 0.67
Taurine 41.45 (11.8) 39.84 (8.22) 0.57 43.3 (11.6) 42.0 (8.8) 0.67
Citrulline 31.47 (12.28) 33.02 (11.75) 0.64 32.7 (13.2) 33.12 (10.5) 0.91
Alanine 573.9 (142.5) 478.8 (182.2) 0.03 722.6 (164.4) 636.1 (206.9) 0.09
Proline 262.9 (197.2–377.8) 214.8 (167.3–323.6) 0.02 458.4 (354.9–512.4) 323.6 (260.4–401.8) 0.02
α ‑Aminobutyric acid 40.5 (27–58.9) 32.8 (25.3–47.5) 0.08 55.3 (36.1–80.2) 36 (27.5–60.1) 0.04
Ornithine 48.3 (42.6–70.3) 45.6 (38–54.8) 0.03 66.7 (54.0–80.1) 55.6 (44.4–73.0) 0.02
Data are presented as mean (SD) or median (interquartile range).
Abbreviations: GIP, glucose ‑dependent insulinotropic polypeptide; GLP ‑1, glucagon ‑like peptide ‑1
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one being a complication of the other (the com­
mon soil hypothesis).
•	  Complications observed in gallstone disease are 
probably not related to the disease as such, but 
higher BCAAs levels might be the cause of type 
2 diabetes mellitus and CVD.
A large multicenter study is necessary to evalu­
ate the relationship between plasma amino acids 
and diabetes, gallstone disease, and CVD.
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et al29 investigated the possibility of employing 
BCAAs to identify an increased CVD risk. They 
observed higher serum concentrations of Val, Ile, 
and Leu in the obese (BMI >30 kg/m2) and over­
weight (BMI, 25.1–30 kg/m2) patients with car­
diometabolic abnormalities than in healthy sub­
jects. The aromatic amino acids, such as Phe and 
Tyr, were increased in the overweight and obese 
patients with cardiometabolic abnormalities com­
pared with subjects without such abnormalities. 
Ornithine concentrations were increased in over­
weight patients with cardiometabolic abnormal­
ities compared with subjects without such ab­
normalities.29 Similar results were obtained in 
the present study, where the levels of these ami­
no acids were higher in the study group than in 
the control group.
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in the study group than in the control group, but 
these differences were not significant. In patients 
with gallstone disease, a higher concentration 
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tions of BCAAs. Similar results were obtained for 
GIP, but these differences were not significant. 
To our knowledge, this is the first study compar­
ing the profile of amino acids and plasma incre­
tin concentrations in patients with gallstones.
In the present study, the mean fasting and 
postprandial values of BCAAs were higher in 
the study group than in the control group, and 
the percentage increase in the concentrations of 
amino acids after a meal were the same in both 
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line concentrations of BCAAs might be biomark­
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tive pathophysiological processes.
Taking into account the results of the present 
study, we hypothesized the following:
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already speculated by Stern32 that both diabetes 
and CVD share common antecedents rather than 
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